Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 19;11(9):e007630. doi: 10.1136/jitc-2023-007630

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Survival outcomes for patients with resected stage III melanoma who were treated outside of clinical trials stratified by primary adjuvant therapy. (A) Median recurrence-free survival was significantly longer for patients given adjuvant TT (31.0 months, 95% CI 26.0 to 36.0 vs 17.0 months, 95% CI 11.9 to 22.1, p<0.001) as compared with adjuvant anti-PD1 therapy. (B) Forest plot illustrating results of multivariate Cox regression for recurrence-free survival and corresponding HR. (C) Cox-adjusted Kaplan-Meier curves for recurrence-free survival (bottom, left) and time point differences in adjusted RFS between patients treated with upfront adjuvant anti-PD1 as compared with upfront adjuvant TT. AJCC, American Joint Committee on Cancer; RFS, recurrence-free survival; TT, targeted therapy. Significance levels: *p<0.05, **p<0.01, ***p<0.001.